- Oops!Something went wrong.Please try again later.
The vaccine, named Covovax, is produced by the Serum Institute of India and is part of the COVAX facility portfolio.
It requires two doses and is stable at 2 to 8 °C refrigerated temperatures.
The vaccine uses a novel platform and is produced by creating an engineered baculovirus containing a gene for a modified SARS-CoV-2 spike protein.
The originator product produced by Novavax, named Nuvaxovid, is currently under assessment by the European Medicines Agency (EMA).
WHO will complete its assessment of this vaccine once the EMA has issued its recommendation.
Price Action: NVAX shares are up 11% at $216.32 during the market session on the last check Friday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.